Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-M 200 vs ISOVUE-300
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar),CT cisternography,Ventriculography
Intravascular administration for radiography (e.g., angiography, urography),Intrathecal administration for myelography,Intracavitary administration for arthrography, hysterosalpingography, etc.
Intrathecal: 8-12 m L (200 mg Iodine/m L) for lumbar myelography. Intravenous: 50-200 m L for contrast enhancement, administered as a bolus or infusion per procedure.
Intravenous: 50-150 m L (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 m L depending on procedure; intrathecal: 8-15 m L. Maximum total iodine dose: 300 mg iodine/kg.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. Prolonged in renal impairment, which may necessitate dose adjustment.
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 m L/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Not metabolized; excreted unchanged by the kidneys. Undergoes passive resorption from cerebrospinal fluid into plasma.
Not metabolized; excreted unchanged by glomerular filtration.
Primarily renal: >90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 1% is excreted via biliary/fecal routes.
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
Negligible, <2% bound to plasma proteins.
Iopamidol (active ingredient) is minimally protein bound (<5%), primarily to albumin.
Approximately 0.3–0.4 L/kg, consistent with distribution into extracellular fluid space.
Approximately 0.20–0.30 L/kg, indicating distribution primarily within extracellular fluid space; low tissue binding.
Not applicable; administered intravenously or intra-arterially, with 100% bioavailability by these routes.
Not applicable for oral route as it is used only intravascularly or intrathecally; bioavailability is 100% for IV injection and near 100% for intra-arterial and intrathecal administration.
e GFR ≥30 m L/min: No adjustment. e GFR <30 m L/min: Contraindicated due to risk of nephrogenic systemic fibrosis (NSF) with gadolinium-based agents; however, for iopamidol-based Isovue-M 200, renal impairment requires dose reduction and careful monitoring. In severe renal impairment (e GFR <30 m L/min), use lowest effective dose and ensure adequate hydration; consider alternative imaging.
GFR <30 m L/min: Use with caution; consider lower dose and ensure adequate hydration. GFR <15 m L/min: Avoid use unless essential; post-procedure hemodialysis may be considered. No specific dose reduction formula; clinical judgment advised.
No specific Child-Pugh based adjustments recommended; use with caution in severe hepatic impairment due to potential for contrast-induced nephropathy and systemic effects.
No specific Child-Pugh based dose adjustments; use cautiously in severe hepatic impairment due to altered pharmacokinetics.
Intrathecal: 0.2-0.4 m L/kg (up to 12 m L total) for myelography. Intravenous: 1.5-2.5 m L/kg (max 200 m L) for CT or angiography, adjusted per procedure.
Weight-based: 1-2 m L/kg (300 mg iodine/m L) intravenously; maximum total dose 300 mg iodine/kg. Adjust for body habitus and procedure.
Use with caution due to increased prevalence of renal impairment, cardiovascular disease, and dehydration. Assess renal function before use; ensure adequate hydration; consider lower doses and longer intervals between procedures.
Elderly patients may have reduced renal function; assess GFR and adjust dose accordingly. Ensure adequate hydration before and after procedure. Monitor for nephrotoxicity and hypersensitivity.
Risk of serious adverse reactions including anaphylaxis, seizures, and neurological complications when administered intrathecally. Use only by physicians trained in myelography and familiar with the procedure. Resuscitative equipment and trained personnel must be immediately available.
No FDA boxed warning.
Risk of anaphylactoid reactions, especially in patients with history of allergy or bronchial asthma,Seizures may occur, particularly in patients with epilepsy or when concurrent medications lower seizure threshold,Renal impairment delays elimination and increases risk of adverse effects,Adequate hydration before and after procedure is essential,Neurotoxicity: avoid hemorrhage or infection at puncture site, do not use in patients with increased intracranial pressure
Risk of serious hypersensitivity reactions (including anaphylaxis),Acute kidney injury in patients with pre-existing renal impairment or other risk factors,Thyroid dysfunction (especially in neonates) due to iodine load,Pregnancy and lactation considerations
Known hypersensitivity to iopamidol or any component of the formulation,Concurrent intrathecal administration of corticosteroids or other contrast agents,Blood in CSF (hemorrhagic puncture) due to increased risk of neurotoxicity,History of seizures or epilepsy (relative contraindication depending on benefit-risk),Severe renal impairment (relative, may be used after dialysis if necessary)
Known hypersensitivity to iopamidol or any components of the formulation,History of severe adverse reaction to iodinated contrast agents
No specific food interactions. Maintain adequate hydration before and after contrast administration. Avoid alcohol consumption for 24 hours post-procedure as it may exacerbate CNS side effects.
No specific food interactions. However, patients are typically advised to avoid solid food for a few hours before the procedure (e.g., 4-6 hours NPO prior to injection) to reduce the risk of aspiration if emesis occurs. Also, ensure adequate hydration: recommend clear liquids (water, juice) unless contraindicated (e.g., pre-procedure fasting for other reasons).
Iopamidol (ISOVUE-M 200) is a nonionic iodinated contrast agent. Animal reproduction studies have not been conducted. It is not known whether iopamidol can cause fetal harm when administered to a pregnant woman. However, iodinated contrast agents cross the placenta and accumulate in the fetal thyroid, potentially causing hypothyroidism. Use during pregnancy should be limited to situations where the diagnostic benefit clearly outweighs the risk. First trimester exposure is not advised due to organogenesis. Second and third trimester use may be considered with caution, but neonatal thyroid function should be assessed after birth.
Iodinated contrast agents like Isovue-300 (iopamidol) cross the placenta. First trimester: Avoid unless essential; theoretical risk of fetal hypothyroidism from free iodide. Second/third trimester: Risk of transient neonatal hypothyroidism if high doses used; fetal goiter reported. No teratogenic effects at clinical doses in animal studies.
Iopamidol is excreted into human breast milk in very small amounts. The milk-to-plasma ratio (M/P) is approximately 0.01. After IV administration, the amount ingested by a nursing infant is minimal (<0.1% of the maternal dose). Because of the low bioavailability of oral iodinated contrast agents, adverse effects in the infant are unlikely. The American College of Radiology considers it safe to continue breastfeeding after use of iodinated contrast agents. However, some guidelines suggest discarding breast milk for 12-24 hours after administration if desired.
Iopamidol is excreted into breast milk in small amounts (<1% of maternal dose). M/P ratio not established. Discontinue breastfeeding for 12-24 hours after administration, or pump and discard. Use only if clearly needed.
No specific dose adjustment is required for iopamidol (ISOVUE-M 200) during pregnancy. However, the lowest effective dose necessary for diagnostic imaging should be used. The physiological changes of pregnancy (increased plasma volume, renal blood flow and GFR) may alter the pharmacokinetics of iopamidol, potentially leading to faster clearance. Nonetheless, no dose adjustment is recommended as contrast dosing is weight-based and the agent is used as a single dose for imaging.
No specific dose adjustments for pregnancy; use lowest effective dose. Increased plasma volume may slightly dilute contrast, but no dose change recommended. Avoid in patients with impaired renal function or hyperthyroidism.
ISOVUE-M 200 (iopamidol) is a nonionic, low-osmolar iodinated contrast medium used for intrathecal administration in myelography. Pre-hydrate patients to reduce risk of contrast-induced nephropathy. Have resuscitation equipment available due to risk of anaphylactoid reactions. Avoid in patients with known hypersensitivity to iodine-containing compounds. Monitor for delayed adverse effects such as headache, nausea, and meningeal irritation.
ISOVUE-300 (iopamidol) is a nonionic, low-osmolality iodinated contrast medium used for intravascular and intrathecal administration. Key pearls: 1) Pre-hydrate patients with normal saline to reduce risk of contrast-induced nephropathy, especially in those with e GFR <30 m L/min/1.73m². 2) Screen for prior allergic-like reactions; consider premedication with corticosteroids (e.g., prednisone 50 mg PO q12h for 3 doses prior) and antihistamines (diphenhydramine 50 mg IV/PO 1 hour before) for history of moderate or severe reactions. 3) Avoid intrathecal use if there is suspicion of elevated intracranial pressure or CSF obstruction. 4) Metformin should be held for 48 hours post-procedure and only resumed after renal function recheck. 5) Have emergency equipment (oxygen, epinephrine, IV access) readily available for treatment of anaphylactoid reactions.
Inform your healthcare provider if you have any allergies, especially to iodine or contrast agents.,Tell your doctor if you have kidney problems, diabetes, or are taking certain medications like metformin.,Drink plenty of fluids before and after the procedure to help flush the contrast from your body.,You may experience headache, nausea, or back pain after the injection; report severe or persistent symptoms.,Avoid driving or operating machinery for at least 24 hours after the procedure due to possible dizziness or drowsiness.,Inform your doctor if you are pregnant, breastfeeding, or suspect you may be pregnant.
This contrast agent may cause a warm sensation or metallic taste during injection; these sensations are temporary.,Notify the technologist immediately if you experience itching, hives, difficulty breathing, or swelling of the face or throat.,You should drink plenty of fluids (water) before and after the procedure to help clear the contrast from your kidneys unless otherwise instructed.,If you take metformin for diabetes, you may need to stop it for 48 hours after the procedure; your doctor will advise when to restart.,Inform your healthcare provider about any allergies (especially to iodine or contrast media), kidney problems, asthma, or if you are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-M 200 vs ISOVUE-300, answered by our medical review team.
ISOVUE-M 200 is a Contrast Media that works by Iodinated radiocontrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during imaging procedures.. ISOVUE-300 is a Contrast Media that works by Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-M 200 and ISOVUE-300 depend on the specific clinical indication. These are both Contrast Media agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-M 200 is: Intrathecal: 8-12 m L (200 mg Iodine/m L) for lumbar myelography. Intravenous: 50-200 m L for contrast enhancement, administered as a bolus or infusion per procedure.. The standard adult dose of ISOVUE-300 is: Intravenous: 50-150 m L (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 m L depending on procedure; intrathecal: 8-15 m L. Maximum total iodine dose: 300 mg iodine/kg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-M 200 and ISOVUE-300 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-M 200 is classified as Category C. Iopamidol (ISOVUE-M 200) is a nonionic iodinated contrast agent. Animal reproduction studies have not been conducted. It is not known whether iopamidol can cause fetal harm when ad. ISOVUE-300 is classified as Category C. Iodinated contrast agents like Isovue-300 (iopamidol) cross the placenta. First trimester: Avoid unless essential; theoretical risk of fetal hypothyroidism from free iodide. Second. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.